Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574401 | 0.91 | RAF1 (0.77) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL16990654 | 0.87 | HDAC1 (0.55) | RAF1KDR | |
| SCHEMBL102637 | 0.87 | RAF1 (0.72) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL13234879 | 0.81 | RAF1 (0.77) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL16990603 | 0.81 | HDAC1 (0.59) | — | |
| SCHEMBL2944830 | 0.81 | RAF1 (0.66) | RAF1RIPK2MAPK13MAPK14MAPK12 | |
| SCHEMBL16990623 | 0.81 | P2RX3 (0.49) | MAPK14 | |
| SCHEMBL15573219 | 0.80 | GRM5 (0.52) | KDRFLT3 | |
| SCHEMBL101749 | 0.80 | RAF1 (0.64) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL15574560 | 0.79 | NPC1 (0.58) | RAF1KDRMAPK13MAPK14CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | RAF1 3072/4885KDR 404/4885RIPK2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.